Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung

Liyang Wu1, Baris Budak1, Oihane Ofogo1

  • 1Institute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.

Insights

Targeting both BCL-XL and MCL-1 simultaneously triggers rapid apoptosis in non-small cell lung cancer (NSCLC) cells. This combined approach overcomes resistance and offers a new therapeutic strategy for NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Non-small cell lung cancer (NSCLC) often resists apoptosis, hindering treatment efficacy.
  • The roles of BCL-2 family proteins in NSCLC survival are complex, especially with frequent p53 mutations.
  • Understanding apoptotic dependencies is crucial for developing effective NSCLC therapies.

Purpose of the Study:

  • To systematically investigate the intrinsic apoptotic dependencies in NSCLC cell lines.
  • To determine if NSCLC survival relies on single anti-apoptotic proteins or a cooperative network.
  • To explore novel therapeutic strategies by targeting specific BCL-2 family members.

Main Methods:

  • Utilized selective BH3 mimetics to target BCL-2, BCL-XL, and MCL-1 in NSCLC cell lines.
  • Assessed sensitization to cisplatin and apoptotic responses to single-agent inhibition.
  • Investigated the synergistic effects of combined BCL-XL and MCL-1 inhibition.
  • Evaluated the role of p53 status and mitochondrial pathways in apoptosis induction.

Main Results:

  • Single-agent inhibition of BCL-2, BCL-XL, or MCL-1 showed limited and variable apoptotic responses in NSCLC.
  • Combined targeting of BCL-XL and MCL-1 induced rapid, synergistic, and irreversible apoptosis in most NSCLC cell lines.
  • This synergistic apoptosis was p53-independent and relied on the mitochondrial machinery (BAX/BAK).
  • Next-generation BCL-XL inhibitors and PROTACs restored apoptosis, addressing target engagement issues.

Conclusions:

  • Apoptotic control in NSCLC is primarily driven by a cooperative network of BCL-XL and MCL-1.
  • Dual targeting of BCL-XL and MCL-1 represents a potent and p53-independent therapeutic strategy for NSCLC.
  • Platelet-sparing BCL-XL inhibitors maintain synergy with MCL-1 inhibition, overcoming translational challenges.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...